Original Publication Date: 29 October, 2018
Publication / Source: Bioanalysis 10(20)
Authors: Shi C, Goldberg S, Lin T et al.
Antibody–drug conjugates (ADCs) hold great promise as therapeutic agents for cancer due to their capability to deliver potent cytotoxic agents to targeted cells, thereby reducing nontargeted exposure, increasing drug concentrations at the disease site and broadening the therapeutic window [1–5]. In recent years, ‘alternative scaffold’ proteins have also emerged as potential therapeutic agents for cancer [6–9]. Designed or natural proteins with simple, stable structures and highly specific affinity for biological targets have been explored to generate